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Objective: Knee replacement (KR) represents a clinically important endpoint of knee osteoarthritis
(KOA). Here we examine the 4-year trajectory of femoro-tibial cartilage thickness loss prior to KR vs non-
replaced controls.
Methods: A nested caseecontrol study was performed in Osteoarthritis Initiative (OAI) participants:
Cases with KR between 12 and 60 month (M) follow-up were each matched with one control (without
KR through 60M) by age, sex, and baseline radiographic stage. Femoro-tibial cartilage thickness was
measured quantitatively using magnetic resonance imaging (MRI) at the annual visit prior to KR
occurrence (T0), and at 1e4 years prior to T0 (T1 to T4). Cartilage loss between cases and controls was
compared using paired t-tests and conditional logistic regression.
Results: One hundred and eighty-nine knees of 164 OAI participants [55% women; age 64  8.7; body
mass index (BMI) 29  4.5] had KR and longitudinal cartilage data. Comparison of annualized slopes of
change across all time points revealed greater loss in the central medial tibia (primary outcome) in KRs
than in controls [94  137 vs 55  104 mm; P ¼ 0.0017 (paired t); odds ratio (OR) 1.36 (95% conﬁdence
interval (CI): 1.08e1.70)]. The discrimination was stronger for T2/ T0 [OR 1.61 (1.33e1.95), n ¼ 127]
than for T1/ T0, and was not statistically signiﬁcant for intervals prior to T2 [i.e., T4/ T2, OR 0.97
(0.67e1.41), n ¼ 60]. Results were similar for total medial femoro-tibial cartilage loss (secondary
outcome), and when adjusting for pain and BMI.
Conclusions: In knees with subsequent replacement, cartilage loss accelerates in the 2 years, and
particularly in the year prior to surgery, compared with controls. Whether slowing this cartilage loss can
delay KR remains to be determined.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.to: F. Eckstein, Institute of
ergasse 21, A5020 Salzburg,
002-1249.
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Knee osteoarthritis (KOA) is estimated to affect >10% of the
population in the United States1 and, although commonly regarded
as a disease of the elderly, symptomatic KOA is diagnosed today at a
mean age of only 56 years, with a lifetime risk of 45%2. KOA istd. All rights reserved.
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Fig. 1. Graph showing the study design and methods: OAI participants with KR
occurrence between 24 and 60 month (M) follow-up had quantitative cartilage anal-
ysis at 2e5 prior time points, providing a minimum of one to a maximum of four 1-
year observation periods.
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causes signiﬁcant morbidity, mortality, and reduction in the quality
of life5, and substantial health care utilization6. In absence of
effective disease modifying therapies, a large portion of the costs
involved in managing KOA is driven by knee replacements (KRs),
and KR therefore represents a clinically important endpoint7. The
number of annual KRs in the US has doubled in the last decade, with
a disproportionate increase amongst younger adults; its prevalence
now is considerably greater than that of rheumatoid arthritis8.
Few studies have examined cartilage loss quantitatively with
magnetic resonance imaging (MRI) prior to KR7,9e12. However,
these prospective cohort studies generally did not adequately
adjust for the fact that knees with advanced radiographic disease
exhibit greater cartilage loss13e15 and also aremore likely to receive
KR than those being at an earlier stage of disease. Using a case/
control design with matching for baseline radiographic disease
stage [Kellgren Lawrence grade (KLG)], sex, and age, we have re-
ported that cartilage thickness loss was signiﬁcantly greater in the
year prior to KR than in control knees that did not subsequently
undergo KR16. However, KOA is a slowly evolving disorder, and 1
year of observation represents a relatively short time period in
relation to the time between incident symptoms or radiographic
signs and need for KR. Elucidating the trajectory of cartilage loss
over several years prior to KR can help in the understanding of how
structural change in KOA progresses prior to that knee reaching a
critical clinical state. Further, this analysis may help in character-
izing potential timewindows for structure modiﬁcation of cartilage
by therapeutic intervention with disease modifying drugs
(DMOADs) or other measures.
The purpose of this study therefore was to examine the trajec-
tory of cartilage loss over 4 years prior to KR, compared with
matched controls that did not undergo KR during this observation
interval. Speciﬁcally, we asked whether cartilage loss between KRs
and control knees differs during observation intervals>1 year prior
to KR.
Methods
Study design
This study was ancillary to the Osteoarthritis Initiative (OAI)
multi-center longitudinal cohort study (http://www.oai.ucsf.edu/
)16,17. The participants were recruited at four centers16e18 and
studied annually over 4 years, using 3 T MRI16e19 and other
methods. OAI participants were 45e79 years old andwith (or at risk
of symptomatic KOA) in at least one knee17. The studywas approved
by the local Institutional Review Boards at each of the sites, and all
participants gave informed consent17. OAI participants were
examined and interviewed annually about having received a KR in
the preceding 12 months (M). This was conﬁrmed by radiography,
or from hospital records when radiographs were not available.
To be eligible as a case, a KR had to be recorded at 24 M, 36M,
48M, or 60M follow-up, and MRI acquisitions acceptable for
quantitative analysis had to be present for at least two prior (but
not necessarily for all preceding) time points (Fig. 1). The annual
MRI examination prior to KR occurrence was termed T0, and the
annual examinations preceding T0 were designated T1 through
T4. KRs detected at 12M were not included, because they did not
have longitudinal data prior to KR. KRs detected at the 24Mhad two
prior annual measurements (T0 and T1), and those observed at
60M had up to ﬁve previous annual measurements (T0 through T4;
Fig.1). If both knees of one participant were replaced at the same, or
at different time points, both were included in the analysis (for
statistical treatment of potentially correlated observations, please
see below).Control knees were selected from those without self-reported
KR and without evidence of KR on radiographs between baseline
and 60M. Knees did not qualify as controls if the opposite knee
received a KR during the study. Controls had to have MRIs available
at time points corresponding with those of the KR cases (T0 through
T4). Cases and controls were matched 1:1 by sex, age (5 years),
and radiographic disease stage, documented by central reading at
the baseline visit (KLG strata of 0e1, 2, 3, and 4). KLGs from release
0.4 from the central readings of the ﬁxed ﬂexion radiographs
(performed at Boston University) were taken17. In a second (post-
hoc) step, attempts were made to match cases with medial joint
space narrowing (JSN) to controls with medial JSN, and cases with
lateral JSN to controls with lateral JSN: 137 cases could be matched
to controls with the same medial/lateral JSN pattern.Quantitative MRI analysis
The quantitative MR image analysis relied on an oblique sagittal
double-echo steady-state (DESS) sequence water excitation17,19e21.
Segmentation of the medial and lateral femoro-tibial cartilages was
performed at one image analysis center (Chondrometrics GmbH,
Ainring, Germany), the readers being fully blinded to case/control
status and to the acquisition order of the different time points16,18.
The total area of subchondral bone (tAB) and cartilage surface area
(AC) of the weight-bearing femoro-tibial compartment were
analyzed16,18, and all segmentations were quality controlled by one
of two experts (SM or FE). The mean cartilage thickness over the
total area of subchondral bone (ThCtAB.Me) was derived after 3D
surface reconstruction, using software by Chondrometrics GmbH
(Ainring, Germany)22. The cartilage thickness was then computed
for the medial and lateral (femoro-tibial) compartments, for the
medial and lateral tibiae and weight-bearing femoral condyles, and
for ﬁve tibial (central, external, internal, anterior, posterior) and
three femoral subregions (central, external, internal)22 (Fig. 2).
Change in cartilage thickness was computed by subtracting the
thickness measured at one time point from that observed at a later
time point; absolute cartilage loss hence was expressed as a
negative value in mm. The change was not reported in percent (%),
because percent values become very high when the cartilage
thickness at the earlier time point is already close to zero.
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Fig. 2. View of the weight-bearing femoral and their subregions from inferior (top), of
the femoro-tibial plates from anterior (middle), and of the tibiae and their subregions
from superior: the central subregion of the medial tibia (cMT) was selected as the
primary, and the total medial femoro-tibial compartment (MFTC) as the secondary
outcome. MT ¼ medial tibia, LT ¼ lateral tibia, cMF ¼ weight-bearing (central) medial
femur, cLF ¼ weight-bearing (central) lateral femur, LFTC ¼ lateral femoro-tibial
compartment.
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All tests were performed using SAS software (version 9.2, SAS
Institute, Cary, NC).
The central subregion of the medial tibia (cMT; Fig. 2) was
selected as the primary analytic outcome, because it had been
shown to best discriminate between KR cases and non-KR controls
in our previous work on longitudinal change over 1 year prior to
KR16. Cartilage thickness in the total medial femoro-tibial
compartment (MFTC) was used as a secondary endpoint, because
it represents the cartilage loss across the entire compartment and
also was shown to discriminate signiﬁcantly between cases and
controls. MFTC cartilage thickness was determined as the sum of
that in the medial tibia and the weight-bearing medial femur
(Fig. 2). Correlations between KR cases and their sex-, age-, and
KLG-matched controls, and correlations between knees of the few
participants with bilateral KRs, were accounted for by general
estimating equation (GEE) models, with an independent working
correlation followed by the robust sandwich estimator for the
covariance matrix of the regression coefﬁcients23,24.
Rates of cMT and MFTC cartilage loss (Fig. 2) were compared
between various longitudinal 1- and 2-year intervals prior to KR,
analyzing the same time intervals relative to baseline between the
KR cases and the matched controls. Slopes of annual cMT and MFTC
cartilage loss were also calculated for each knee using knee-speciﬁc
linear regressions vs time, making use of all available time points.
Statistical comparisons included paired t-tests between case/con-
trol pairs, and caseecontrol conditional logistic regression odd ra-
tios (ccOR) per standard deviation (SD). Robustness of these
comparisons was assessed by performing additional adjustment for
the effects of baseline body mass index (BMI) and pain at the start
of each observation interval (ccORbp). These adjustments were
made for standard categories of the BMI (normal/overweight/
obese) and for standard categories of pain frequency status in the
past year, commonly used to classify symptomatic KOA (no pain/
infrequent pain/frequent pain). Values reported at the beginning ofeach observation interval (i.e., at T2 for the T2 / T1 interval)
were used for that purpose. These adjustments weremade to verify
whether the crude comparisons were robust, because previous
studies have shown an association of cartilage loss with BMI and
pain25e27. Pain frequencywas used rather than theWestern Ontario
and McMaster Universities Arthritis Index (WOMAC), because pain
frequency questions asked by the OAI (Did you have pain on most
days of the month, in at least one of the past 12 months?) cover a
much longer period than the WOMAC, and because in contrast to
pain frequency26,27, WOMAC was not found to be signiﬁcantly
associated with subsequent cartilage loss in a recent study28.
Caseecontrol areas under the receiver operation curve
(ccAUC)29 were calculated to allow for direct comparison with our
previous report16. Sensitivity analyses were performed by
repeating the above analyses after excluding case/control pairs
with a mismatch in baseline medial/lateral JSN status. Given pre-
vious observations of superior discrimination between case/control
pairs with “early” baseline radiographic disease status16, the above
analyses were also conducted in a stratum of KLG 0e2 knees.
Results
Sample description
Two hundred and twenty-two knees of 192 OAI participants
received a KR between 24M and 60M (37 at 24M, 60 at 36M, 58 at
48M, and 67 at 60M; Fig. 1). Of these, 189 from 164 participants
(55% women; age 64  8.7; BMI 29  4.5) had a matched control
and MRI readings for at least two prior time points to calculate
longitudinal cartilage loss. Of the case/control pairs, nine were
baseline KLG0, nine KLG1, 40 KLG2, 71 KLG3, and 60 KLG4. One
hundred and eighty-nine had total KR, eight partial medial KR, and
one patello-femoral replacement.
central subregion of the medial tibia (cMT): primary analytic focus
Analysis of slopes of annual change from the available time
points revealed signiﬁcantly greater rates of cartilage loss in the
central subregion of the medial tibia (cMT) in KRs (94  137 mm
p.a.) than in controls (55  104 mm p.a.). The difference was sta-
tistically signiﬁcant with and without adjustment for potential
confounders (P ¼ 0.0017 for paired t-test, P ¼ 0.008 for the unad-
justed, and 0.014 for BMI and pain frequency adjusted conditional
logistic regression model). The ccOR was 1.36 [95% conﬁdence in-
terval (CI): 1.08e1.70] without, and 1.34 (95% CI: 1.06e1.70) with
adjustment for BMI and pain frequency. The ccAUC adjusting for
matching variables was 0.60 (95% CI: 0.54e0.65).
When examining the trajectory of cartilage loss during the
annual time intervals prior to KR, the ratio of cMT cartilage loss in
KRs vs controls was 2.92:1 during T1/ T0 (n¼ 152), 1.72:1 during
T2/ T1 (n ¼ 123), 1.13:1 during T3/ T2 (n ¼ 94), and 0.64:1
during T4 / T3 (n ¼ 56) [Table I; Fig. 3(A)]. The difference
attained statistical signiﬁcance for T1/ T0, but not for preceding
time periods. When restricting the analysis to cases with T1/ T0
data that also had T2/ T0 and T2/ T1 data available (n¼ 127),
the rate of change was very similar to that observed in the larger
sample. The observed cMT cartilage loss was greater in controls
than in KR cases during T4/ T3 [Table I; Fig. 3(A)].
When restricting the analysis to the 137 femoro-tibial KRs
matched with controls based on the same medial/lateral JSN status
(also excluding the one patello-femoral KR), slope analysis
conﬁrmed signiﬁcantly greater rates of cartilage loss in KRs
(105  141 mm p.a.) than in controls (64  110 mm p.a.). Again, the
differencewas statistically signiﬁcant with andwithout adjustment
for potential confounders, the ccOR being 1.39 (95% CI: 1.04e1.86)
Table I
Rates of cartilage loss (mean  SD) in the central subregion of the medial tibia (cMT; primary analytic focus; see Fig. 2) in cases with KR vs matched controls
T4/ T3
(n ¼ 56)
T3/ T2
(N ¼ 94)
T2/ T1
(n ¼ 123)
T1/ T0
(n ¼ 152)
T4/ T2
(n ¼ 60)
T2/ T0
(n ¼ 127)
Total KR sample
KRs (mm) 55  198 61  152 86  184 114  207 119  255 209  281
Controls (mm) 86  147 54  119 50  137 39  159 125  175 61  156
P (paired t) 0.3334 0.7211 0.0913 0.0007 0.8612 <0.0001
ccAUC
[95% CI]
0.57
[.46e.68]
0.48
[.40e.57]
0.53
[.45e.60]
0.59
[.52e.65]
0.51
[.41e.62]
0.66
[.60e.73]
ccOR
[95% CI]
0.85
[.59e1.22]
1.05
[.79e1.39]
1.21
[1.00e1.47]
1.42***
[1.16e1.72]
0.97
[.67e1.41]
1.61***
[1.33e1.95]
ccORbp
[95% CI]
0.85
[.54e1.35]
1.06
[.80e1.40]
1.19
[0.98e1.45]
1.48***
[1.20e1.82]
1.21
[.83e1.76]
1.64***
[1.34e1.99]
T4/ T3
(n ¼ 38)
T3/ T2
(N ¼ 69)
T2/ T1
(n ¼ 88)
T1/ T0
(n ¼ 111)
T4/ T2
(n ¼ 41)
T2/ T0
(n ¼ 86)
Excluding patello-femoral KR and femoro-tibial KRs with medial/lateral JSN mismatch
KRs (mm) 80  226 66  167 113  199 112  183 146  297 230  252
Controls (mm) 82  162 56  128 55  142 60  160 123  195 79  161
P (paired t) 0.9687 0.6725 0.0348 0.0314 0.6406 <0.0001
ccOR
[95% CI]
0.99
[.69e1.43]
1.07
[.77e1.48]
1.32*
[1.06e1.64]
1.31*
[1.03e1.68]
1.10
[.73e1.66]
1.77***
[1.37e2.30]
ccORbp
[95% CI]
1.00
[.66e1.51]
1.09
[.80e1.49]
1.29*
[1.03e1.63]
1.41*
[1.08e1.84]
1.29
[.83e2.02]
1.83***
[1.35e2.48]
*P < 0.05; ***P < 0.001; T0 ¼ annual MRI examination time point prior to KR occurrence; T1, T2, T3, and T4 ¼ time points preceding T0 by 1, 2, 3 and 4 years respectively.
T4/ T3 hence represents an observation interval 4 to 3 years prior to the last measurement before KR (only available from 60M follow-up KRs), T3/ T2 an observation
interval 3 to 2 years prior (available from 48M to 60M follow-up KRs), T2/ T1 an observation interval 2 to 1 years prior (available from 36M, 48M and 60M follow-up KRs),
and T1/ T0 an observation interval 1 year prior to the last measurement before KR (available from 24M, 36M, 48M and 60M follow-up KRs); T4/ T2 represents an
observation interval 4 to 2 years prior to the last measurement before KR, and T2/ T0 an interval 2 years prior to the last measurement before KR. ccAUC: area under the
curve from logistic regression model for cartilage loss discriminating KR cases from controls, adjusted for caseecontrol baseline matching variables (age, gender, KLG); ccOR,
conditional logistic regression ORs adjusted baseline matching variables; ccORbp: ccOR after adjusting out the effects of baseline BMI and pain at the start of each interval. ORs
are based on standardized measures (per SD of cartilage loss in each “change” interval). All p values that were <0.05 were presented in italics.
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pain frequency. The ratio of cMTcartilage loss between KR cases and
controls was 1.87:1 during T1/ T0, 2.05:1 during T2/ T1,1.18:1
during T3/ T2, and 0.98:1 during T4/ T3 [Table I; Fig. 3(B)].A
B
Fig. 3. Observed rates of cartilage loss (mean and upper 95% CI) in the central subregion o
matched, non-replaced controls [same sex, age (5 years) and baseline KLGs (values are wit
the 95% CIs. (A) Total KR sample. (B) Subsample of femoro-tibial KRs without medial/lateraThe difference attained statistical signiﬁcance for T1/ T0 and for
T2/ T1, but not for preceding time intervals [Table I; Fig. 3(B)].
The strongest difference in cMT cartilage loss between KRs and
controls was observed for the 2-year interval prior to KR occurrencef the medial tibia (cMT; see Fig. 2) over 4 years prior to the occurrence of KRs and in
hout adjustment for pain frequency and BMI)]. The error bars show the lower limits of
l JSN mismatch.
F. Eckstein et al. / Osteoarthritis and Cartilage 22 (2014) 1542e15491546(T2/ T0; Table I). The ratio of longitudinal cartilagewas 3.43:1 for
all KRs, and 2.91:1 for the subsample of femoro-tibial KR/control
pairs with medial/lateral JSN match. No signiﬁcant difference in
cartilage loss was found during T4/ T2 (Table I).
MFTC: secondary analytic focus
The results in the total MFTC were similar to those observed in
cMT (Table II). Again, the slope analysis of annual change from the
available time points revealed signiﬁcantly greater rates of cartilage
loss in KRs (117  178 mm p.a.) than in controls (70  102 mm p.a.),
the difference being statistically signiﬁcant with and without
adjustment for potential confounders (P < 0.001). The ccOR was
1.31 (95% CI: 1.14e1.50) without, and 1.31 (95% CI: 1.11e1.53) with
adjustment for BMI and pain frequency; the ccAUC was 0.56 (95%
CI: 0.50e0.62). Again, the cartilage change during T2 / T0
discriminated best between KR cases and controls, and results were
similar when only including femoro-tibial KR/control pairs with
medial/lateral JSN match (Table II).
Subsample with baseline KLG 0e2
In the KLG 0e2 case/control pairs (n ¼ 58), slope analysis
revealed substantial cMT cartilage loss in KRs (79  134 mm) but
almost no loss in controls (4  51 mm); the difference was statis-
tically signiﬁcant with and without adjustment for potential con-
founders (P  0.002). The ccOR was 2.90 (95% CI: 1.49e5.64)
without, and 2.55 (95% CI: 1.25e5.21) with adjustment for BMI and
pain frequency (Table III); the ccAUC was 0.70 (95% CI: 0.60e0.79).
Discussion
This is the ﬁrst study to report the trajectory of knee cartilage
loss for up to 4 years prior to KR, and the ﬁrst to compare the
observed trajectory with that of matched, non-replaced controls.
The current work extends previous studies7,16 in several ways: (1) It
included up to ﬁve annual time points prior to KR, allowing us to
explore the rate of cartilage loss rates over 4 years before the knees
reached a critical clinical endpoint; (2) it included additional KR
cases from the OAI recorded at 60M follow-up, adding statisticalTable II
Rates of cartilage loss (mean  SD) in the total medial femoro-tibial compartment (MFT
T4/ T3
(n ¼ 56)
T3/ T2
(N ¼ 94)
T2/ T
(n ¼ 123
Total KR sample
KRs (mm) 78  219 83  191 95  2
Controls (mm) 74  166 69  110 71  1
P (paired t) 0.9108 0.5287 0.3100
ccAUC
[95% CI]
0.51
[.40e.61]
0.48
[.40e.57]
0.52
[.44e.59
ccOR
[95% CI]
1.02
[.75e1.38]
1.07
[.88e1.29]
1.12
[.92e1.3
ccORbp
[95% CI]
1.10
[.79e1.52]
1.07
[.88e1.30]
1.12
[.92e1.3
T4/ T3
(n ¼ 38)
T3/ T2
(N ¼ 69)
T2/ T
(n ¼ 88)
Excluding patella-femoral KR and femoro-tibial KRs with medial/lateral JSN mism
KRs (mm) 99  245 103  207 111 
Controls (mm) 75  166 75  110 72  1
P (paired t) 0.5727 0.3371 0.2166
ccOR
[95% CI]
1.13
[.80e1.58]
1.12
[.90e1.38]
1.17
[0.94e1.
ccORbp
[95% CI]
1.10
[.72e1.67]
1.14
[.92e1.41]
1.17
[.93e1.4
*P < 0.05; ***P < 0.001. For abbreviations, please see Table I. All p values that were <0.0power to our previous analysis16; (3) mismatch of medial/lateral
JSN between cases and controls with identical KLG was reduced
post-hoc, by optimizing the matching criteria based on JSN location,
and by performing sensitivity analyses in only those femoro-tibial
KR cases/control pairs without medial/lateral JSN mismatch.
The T0, T1, T2, T3, T4 approach was selected to “synchronize”
the observations of cartilage thickness change in relation to the
time point of the KR. Doing this, we found that, in knees that had
KR, the annual (medial) cartilage thickness loss was signiﬁcantly
(and substantially) greater in the 2 years prior to KR, compared to
that in control knees without KR, but matched for age, sex, and
baseline radiographic status. The differences in cartilage loss
became less over time when moving back to earlier (annual) time
intervals. The strongest difference between KR cases and matched
controls was observed for T2 / T0, whereas no signiﬁcantly
different rates of cartilage loss were observed during the 2-year
interval preceding the above (T4/ T2), or during 1-year intervals
prior to T2 (T4/ T3 or T3/ T2). A similar trajectory of dif-
ferences between KR cases and non-KR controls was previously
reported for knee symptoms30 and parallels those observed here
for cartilage loss. A limitation of the study is that different sample
sizes were available for time periods of different duration for
observing cartilage loss prior to KR. Only KRs occurring at 60M had
all time intervals between T4 and T0 available, whereas knees with
a KR at 24M only contributed T1 and T0. However, because knees
with very different grades of clinical and radiographic OA were
included in the OAI cohort, there is no reason to assume that those
with a KR at 24M were “faster progressors” than those with a KR at
60M, as they may already have been at a more advanced stage of
disease at baseline. Also, the statistical analyses were not per-
formed between periods, but between cases and matched controls
within these periods, with the same time points (relative to base-
line) being compared in cases versus controls. The current study
focused on two speciﬁc anatomical regions of interest, cMT and
MFTC. This choice was made because we previously found that the
difference in cartilage loss between KRs and matched controls in
the year prior to KR was greater in the medial than in the lateral
femoro-tibial compartment, and greater in central than in periph-
eral subregions16. However, results for other cartilage subregions
were thoroughly documented over 1 year prior to KR in ourC) (secondary analytic focus; see Fig. 2) in cases with KRs vs matched controls
1
)
T1/ T0
(n ¼ 152)
T4/ T2
(n ¼ 60)
T2/ T0
(n ¼ 127)
25 146  323 169  279 254  414
58 59  163 138  194 97  189
0.0027 0.4475 0.0002
]
0.55
[.48e.61]
0.53
[.43e.64]
0.60
[.53e.67]
6]
1.30***
[1.13e1.51]
1.13
[.84e1.53]
1.40***
[1.19e1.64]
6]
1.32***
[1.14e1.53]
1.60
[0.99e2.59]
1.42***
[1.21e1.66]
1 T1/ T0
(n ¼ 111)
T4/ T2
(n ¼ 41)
T2/ T0
(n ¼ 86)
atch
247 138  252 210  321 259  355
64 84  156 157  203 115  186
0.0505 0.3322 0.0013
44]
1.24*
[1.03e1.50]
1.21
[.86e1.72]
1.46***
[1.18e1.80]
6]
1.30*
[1.05e1.60]
1.57
[0.94e2.64]
1.50***
[1.22e1.86]
5 were presented in italics.
Table III
Rates of cartilage loss (mean  SD) in the central subregion of the medial tibia (cMT) in the subcohort of cases and matched controls with a baseline KLG 0e2
T4/ T3
(n ¼ 22)
T3/ T2
(N ¼ 32)
T2/ T1
(n ¼ 39)
T1/ T0
(n ¼ 44)
T4/ T2
(n ¼ 23)
T2/ T0
(n ¼ 42)
KRs (mm) 18  167 20  92 64  215 143  263 22  147 249  359
Controls (mm) 51  125 20  83 23  110 37  109 68  146 5  105
P (paired t) 0.1292 0.9985 0.3100 <0.0001 0.2708 <0.0001
ccAUC
[95% CI]
0.61
[.44e.78]
0.52
[.37e.67]
0.52
[.39e.65]
0.72
[.61e.83]
0.55
[.38e.72]
0.74
[.63e.85]
ccOR
[95% CI]
0.56
[.26e1.21]
1.00
[.45e2.21]
1.23
[.86e1.74]
2.86***
[1.45e5.65]
0.64
[.34e1.23]
2.54**
[1.38e4.65]
ccORbp
[95% CI]
0.28
[.03e2.47]
1.09
[.38e3.17]
1.23
[.88e1.73]
3.32**
[1.33e8.29]
0.96
[.41e2.27]
2.72**
[1.66e4.44]
*P < 0.05; **P < 0.01; ***P < 0.001. For abbreviations, please see Table I. Results for the subsample excluding femoro-tibial KRs with medial/lateral JSN mismatch were not
provided, because of the low number of observations. All p values that were <0.05 were presented in italics.
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but were less discriminatory than cMT16. The results (AUCs) re-
ported here for T1/ T0 cartilage thickness loss are similar to those
previously reported for cMT and MFTC in the smaller sample, not
including 60M KRs16.
At ﬁrst impression, it may appear counterintuitive that
discrimination for T2/ T0 was superior to that for T1/ T0 in the
total KR sample (including partial medial/lateral JSN mismatch),
given that T2/ T1 differences in case/control pairswere less than
T1/ T0 differences. However, quantitative measures of cartilage
loss are subject to testeretest errors20,22,31e34, which become
particularly important when relatively small longitudinal changes
are measured over relatively short observation periods18. In the
current and in previous studies35, the magnitude of a 2-year change
was approx. twice that of a 1-year change, whereas the precision
errors can be assumed to be similar for both observation periods.
The ratio between the magnitude of change and these errors is
hence more favorable for longer observation intervals35. Although
the “true change” during T1/ T0may bemore discriminative than
that during T2/ T0, the “observed changes” for T2/ T0 may be
less variable and hence more robust for differentiating rates of
structural progression between KR cases and controls.
The medical treatment for OA is currently restricted to control
symptoms, and if that fails, KR remains the only therapeutic option.
Yet, while KR is a highly effective treatment for end-stage KOA, KR
recipients can experience persistent pain and severe complications
after the intervention8. Further, many patients will require revision
surgery, particularly with life expectancy continuing to increase,
and with KR being performed (or required) at increasingly younger
age8,36. Currently, no medical intervention has been approved for
disease (i.e., structure-) modifying therapy of KOA by a regulatory
agency. Regulatory guidance for approval of disease-modifying
intervention recommends that reduction or prevention of pathol-
ogy in joint tissue should be accompanied by beneﬁts in clinical
outcomes37. The state at which KR is medically indicated is asso-
ciated with strong pain and functional limitation, and severe
reduction in quality of life; KR therefore may be considered as ul-
timate joint “death” or “failure” and therefore represents a very
relevant and important clinical outcome7.
The current and our previous studies16 are unique in that they
compare the rate of cartilage loss between KRs and controls by fully
controlling for baseline radiographic disease stage. In previous
cohort studies7,9,12, those with advanced radiographic disease
(higher KLGs) had a greater likelihood of receiving a KR, and it is
known that knees with higher KLG and/or JSN grades exhibit
greater cartilage loss (and other structural features of disease) than
those with less severe radiographic disease13,14,18. The AUCs and
ORs reported here for cartilage loss have to be interpreted with the
stringent baseline matching for KLG in mind: Compared with
diagnostic imaging methodology used in osteoporosis, the currentapproach resembles one by which a (new) microstructural imaging
method is compared longitudinally in subjects prior to a bone
fracture versus controls without, with subjects matched for baseline
bone mineral density (BMD). Our ﬁndings would be equivalent to
that of the microstructural imaging method being shown to pro-
vide discrimination of bone fracture status by longitudinal differ-
ences in bone microarchitecture, in the absence of baseline BMD
differences between fracture cases and non-fractured controls.
Other structural features of KOA (i.e., effusion, meniscus, bone
marrow lesions) and their longitudinal changes may be co-linearly
related to the cartilage thickness change and risk of KR observed
here. The current paper did not aim to assess causal relationships,
but to evaluate quantitative MRI cartilage measures as “prognostic”
markers38. In future studies, quantitative cartilage loss examined by
MRI may be examined side-by-side with other (clinical, radio-
graphic, MRI-based, molecular) markers, to identify which (com-
bination of) marker(s) is most efﬁcient in predicting the risk of
KR, and potentially also in evaluating the efﬁcacy of structure-
modifying intervention.
In conclusion, this ﬁrst study on the longer-term trajectory of
cartilage thickness change prior to KR shows that cartilage loss
accelerates in the 2 years before, and particularly in the year before,
KR surgery, compared to matched control knees. Observed differ-
ences in case/control pairs were strongest during a 2-year mea-
surement interval prior to KR, but did not reach statistical
signiﬁcance during previous time intervals. Whether slowing this
cartilage loss, by pharmacological or other interventions, can delay
KR surgery remains to be determined.Contributions
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